Kjersem, J B <br/><br/>
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.  [electronic resource] 

 -  The pharmacogenomics journal  06 2016 
 - 272-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-1150 
<br/><br/><label>Standard No.: </label>10.1038/tpj.2015.54  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biomarkers, Tumor--genetics<br/>Clinical Trials, Phase III as Topic<br/>Colorectal Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Fluorouracil--adverse effects<br/>Genetic Association Studies<br/>Genotype<br/>Humans<br/>Male<br/>Middle Aged<br/>Multidrug Resistance-Associated Protein 2<br/>Neoplasm Metastasis<br/>Organoplatinum Compounds--adverse effects<br/>Oxaliplatin<br/>Pharmacogenomic Variants--genetics<br/>Phenotype<br/>Polymorphism, Single Nucleotide<br/>Randomized Controlled Trials as Topic<br/>Retrospective Studies<br/>Risk Factors<br/>Scandinavian and Nordic Countries<br/>Time Factors<br/>Transaminases--genetics<br/>Treatment Outcome<br/>Xeroderma Pigmentosum Group D Protein--genetics<br/>Young Adult